Nuvation Bio Inc. (NUVB) Amends Protocol on Safusidenib Trials in Astrocytoma

The amended protocol expands diligent eligibility successful the registration information of the trial. It volition besides enroll a non-pivotal single-arm cohort to analyse the efficacy and information of safusidenib successful chemotherapy- and radiotherapy-naïve patients. The institution has already delivered affirmative Phase 2 proceedings results, including some astrocytoma and oligodendroglioma.

“These SIGMA protocol updates bespeak alignment with U.S. regulators to enactment the imaginable support of safusidenib arsenic swiftly arsenic imaginable for a diligent colonisation that is successful dire request of options,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio.

Nuvation Bio Inc. (NYSE:NUVB) has already reiterated its committedness to identifying biomarkers and targeting circumstantial mutations to make precise therapies. It is portion of a broader program to code captious needs successful oncology.

While we admit the imaginable of NUVB arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 13 Best Manufacturing Stocks to Invest In Now and 11 AI Stocks That Will Go to the Moon.

Disclosure: None.  Follow Insider Monkey connected Google News.